Paresthesias: A case series study

García, José Aznarez; Lax, N. Garcia; Rico, M. Palao; Espinosa, Isabel Pellicer; Navarro, Mar

doi:10.1016/j.jns.2017.08.1062

Journal of the Neurological Sciences

2017

DOI: 10.1016/j.jns.2017.08.1062

|View full text |Cite

Paresthesias: A case series study

José Aznarez García

N. Garcia Lax

M. Palao Rico

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Multiple Sclerosis: Current Knowledge of the Pathology and Use of Monoclonal Antibodies as a Promising Therapy

Castellón-Arias,

Gazel-Meléndez,

Guido-Villalobos

et al. 2023

Borneo J Pharm

View full text Add to dashboard Cite

Multiple sclerosis is an autoimmune condition characterized by an inflammatory condition and neuron demyelination, leading to a significant deterioration in the patient's quality of life as the disease progresses. The immune system reactivity in this pathology is mainly mediated by reactive T lymphocytes against myelin. The harmful substances production and proinflammatory cell infiltration occur. Currently, there is no cure, so treatment focuses on reducing the development of the individual's long-term disability by addressing symptoms, acute exacerbations, and slowing progress. The traditional treatment includes immunosuppressive substances such as corticosteroids and interferons. However, an approach to more specific, highly effective therapies such as monoclonal antibodies is currently being sought. Ofatumumab, ocrelizumab, alemtuzumab, and rituximab are commercialized monoclonal antibodies. Likewise, therapies in the research phase, such as ublituximab, inebilizumab, GNbAC1, and elezanumab, can be found. Therefore, research must continue to have more information to increase the availability of therapeutic options for patients.

show abstract

Multiple Sclerosis: Current Knowledge of the Pathology and Use of Monoclonal Antibodies as a Promising Therapy

Castellón-Arias,

Gazel-Meléndez,

Guido-Villalobos

et al. 2023

Borneo J Pharm

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Paresthesias: A case series study

Cited by 1 publication

References 0 publications

Multiple Sclerosis: Current Knowledge of the Pathology and Use of Monoclonal Antibodies as a Promising Therapy

Multiple Sclerosis: Current Knowledge of the Pathology and Use of Monoclonal Antibodies as a Promising Therapy

Contact Info

Product

Resources

About